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CHAPTER 1

INTRODUCTION

Aging
Aging is the complex process of metabolic decline over time. This decline is
expressed outwardly through visual markers such as graying hair, wrinkles, increased
adiposity, lack of mobility, and the slowing of other physical functionalities.
Interestingly enough, the extensiveness of the rate at which an individual ages is unique
and depends on a culmination of factors including genetic predisposition, lifestyle,
environment, and overall wellness. During the birth of aging studies, researchers
attempted to make sense of what they thought to be a natural phenomenon. Pooling what
scientific and theoretical information was available at the time in an attempt to
understand why, how, and when aging occurs; yet, failing to adequately provide
reasoning for this happening. In fact, in years past scientists recognized oddities in aging
reflected at the genetic, cellular, and dietary level; where biological processes and
consumption play a part in influencing lifespan.1 For example, calorie restriction is the
maintenance of a low calorie diet without malnourishment and for reasons unknown it
has been linked to longevity.2 Experiments testing calorie restriction on rat growth in
association to lifespan by limiting the calorie intake of mice while supplying them with
1

all of the essential proteins vitamins, and minerals necessary to live resulted in the
rodents with restrictive or the most restrictive diets living the longest.3–5 Many theories
have developed as to why aging occurs. The question as to whether aging is a
programmed part of human nature or induced by some other device has been
investigated. Natural selection is the idea that the weaker less able members of society
come to demise over time.6 Based on evolutionary genetics, two the mutation
accumulation theory and the antagonistic pleiotropy theory challenged the assumption
that natural selection solely impacted aging. The mutation accumulation theory attributed
aging to the buildup of late-acting alleles from perpetuating germline mutations over
successive generations leading to aging.1,6 While the antagonistic pleiotropy theory
associated aging to the fact that certain pleiotropic genes that positively affect fitness at
early ages have a negative impact on fitness in the later stages of life, which is expressed
through aging.1,6 As advancing thought progressed in the late 20th century, viability
studies for various model organisms showed convergence at comparable positions.7 This
indicated the existence of some form of a systemic biological regulatory pathway in the
aging process. In other words, aging may not be initiated at the same time or occur at the
same rate for various organisms but it exists and living beings reach a pivotal point as
time progresses where mortality is more and more likely, becoming inevitable.
Researchers moved from theoretical analysis on the mechanisms of aging to
carrying out experimentation and performing physical examinations on people suffering
from age associated ailments. During the 1950s, age related diseases starting with
progeria and its various forms began being identified and explored.8 Progeria is a
medical term that means prematurely old and was used to classify individuals with

2

suffering from specific type of early senility.8 The nematode Caenorhabditis elegans
became an ideal model for aging research because this model’s lifespan could be
manipulated by environmental agitations such as food availability and temperature.9
Michael Klass selectively bred these nematodes and found that certain mutants lived
longer than their wild type controls.10 The fundamental studies that took place on C.
elegans paved the way for researchers to find genetic markers associated with maturing.11
For instance, David Freidman and Thomas Johnson isolated the same long lived mutant
groups as Klass and reported that one group of mutants with the recessive age-1 gene had
a mutation that decreased the group’s activity, which Friedman and Johnson
phenotypically referred to as uncoordinated (Unc).12,13 This mutation was found to be in
what was later known as phosphatidylinositol 3-kinase (PI3-K).14 Age-1 encodes for a
PI3-K that functions on the insulin/insulin-like growth factor 1 (IFG-1) signaling
pathway (IIS).
Thomas Johnson and William Wood showed that there was a significant
genetically inherited component of longevity that could be manipulated to increase
lifespan based on selective breeding in worms along IIS, the first major pathway shown
to influence aging.15,16 Further analysis showed that other elements along this pathway
extended life in these worms, like the regulatory gene that encodes for IFG-1 known as
daf-2 and its downstream targets.17–20 In order for daf-2 to increase lifespan, the activity
of the FOXO family transcription factor DAF-16 is required. However, upregulation of
DAF-16 can solely trigger dauer formation and influence age related disorders and
longevity in C. elegans.14,17,21 Life extension in C. elegans due to genetic modification
along IIS has extended the lifetime of this model from 1.5 times to 10 times its normal
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lifespan.22 Further studies in other taxa such as flies, mice, and humans have shown that
alterations in genetic markers along IIS can subsequently influence these organisms’
aging as well.23–27 Still too, the sequence homology between a yeast pro-longevity
protein called SCH9 to AKT-1/AKT-2 in IIS exposed a potential conservation of the
aging process from yeast to humans.28 This relationship was derived from the fact that
yeast are single celled organisms without the hormone signaling that exists in humans;
thus implicating an evolutionary conserved process.14
While research on aging has advanced there is still a way to go in completely
understanding how and why aging occurs. Single molecule drugs are now able to
prolong life in mammals but not to the extent that calorie restriction has been able to.14
Calorie restriction has been effective at doing so because it affects multiple longevity
pathways some of which are possibly still undiscovered.14 Studies treating aging
ailments by combining the pharmaceutical drugs, metformin and rapamycin, have
increased lifespan in mice by 20% more than either drug could do alone.29,30 Current
research on humans has found that innate polymorphisms along the IIS pathway have
been associated with increased longevity and health in humans.31–35 Understanding the
biological mechanisms of aging and how these processes influence overall health and
well being will help scientists and medical professionals develop improved treatment
options and management techniques those suffering from age related ailments.

Metabolism
According to the laws of thermodynamics, metabolism maintains homeostasis and
minimum disorder in organisms.36 An organism utilizes outside energy sources to
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internally make use of what is needed to preserve its life and its highly organized state.37
Metabolism consists of all of the biochemical processes of the body essential for energy
production and usage and is divided into three categories: anabolism, catabolism, and
waste disposal.38 Anabolism is the energy requiring processes of the synthesis of
complex macromolecules from simple molecules; catabolism is the energy releasing
activities of macromolecular degradation; and waste disposal consists of a number of
biochemical procedures needed for the elimination of harmful substances from the body
due to molecular synthesis and chemical breakdown.38 The energy that is required for
life is harnessed from food sources such as carbohydrates, proteins, and lipids which are
broken down in order to fuel the body’s ability to function metabolism.
Scientists have spent a vast amount of time and effort in understanding how
metabolism works using what knowledge they have gained to study the individual
metabolic pathways, how they function, how they interact with one another, and how the
pathways work to together. The 1920’s through 1960’s marked an important age in
metabolic research because it was during this period that the cycles and pathways were
discovered; these pathways include glycolysis, cellular respiration, the citric acid cycle,
the urea cycles, glycogen catabolism, oxidative phosphorylation, and ATP energy
transfer reactions.38 After which, researchers were able to determine what was the
preferred biological energy source for the body, what fuels respiration to body and its
tissues such as the liver, kidney, cardiac muscle, and skeletal muscle, and how energy
sources are selected within these tissues.39 Soon investigative pursuits into metabolism
focused on its association to illness and disease. For instance, in an attempt to study
diabetes mellitus, a metabolic disorder resulting from a defect in the uptake of glucose by
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tissues in the body leading to a buildup of glucose in the body.40 An article from 1972
discusses ants swarming the sugary urine of patients suffering from diabetes mellitus over
patients with diabetes insipidus.41 Diabetes insipidus arises from hormonal abnormalities
that cause the body to pass an unusually large volume of dilute and odorless urine.42 As a
result, a person with this disease may experience unquenchable thirst as their body tries
to obtain the fluids that it is losing in large amounts.42 Diabetes mellitus, which includes
type 1 and type 2 diabetes, results in frequent urination and thirst due to the body’s
inability to properly utilize glucose as an energy source.42
Scientists also were interested in the genetic contribution to metabolic illness and
used genetic markers to relate certain diseases to the metabolic state.43 Drug
development led to the study of small molecule metabolism, where small molecules
involved in metabolism were associated with one another based on their biological
activities and drugs that were used to treat illnesses were made to affect the behaviors of
these molecules by binding to them.44–47
Metabolism has been found to be highly conserved and integrated with the most
basic biological systems working together to do what is needed to maintain life.48,49 In
order for cohesive operation, pathway regulation is required. In other words, there has to
proper communication and functioning between these biological systems so that the body
can work as it should to maintain life. The phosphatidylinositol 3-kinase/Akt/
mammalian target of rapamycin (PI3K/Akt/mTOR) pathway promotes anabolism and
suppresses catabolism while AMP-activated protein kinase (AMPK) does the opposite.38
AMPK is a nutrient and energy sensor that activates catabolic pathways and represses
anabolic pathways when the AMP/ATP ratio in the cell rises.23 Nutrient sensing is the
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cell’s ability to use what the body ingests as food for energy and cell growth, and when
coupled with metabolic concentration impacts aging. Both AMP kinase and mTOR
(mechanistic target of rapamycin, a downstream target of IIS) have been shown to
regulate aging in multiple organisms.23,50–52 All of the previously mentioned systems
operate in a network of complexity with one pathway signaling or providing feedback to
the other.14
Communication between tissues occurs through extracellular signals, hormones, and
genes encoding regulatory isoforms that are controlled by cellular processes such as
mRNA transcription, splicing, translation, and stability.53 Cells also regulate enzyme
function through post translational modifications as a means of communicating with one
another; these modifications provide a feedback mechanism for metabolite concentration
that act as substrates for post translational modification reactions.54 Metabolic flux is
regulated by small molecules that affect allosteric enzymes.55 More specifically,
metabolic flux for a given reaction is contingent on the activity level of the catalyzing
enzyme, the properties of the enzyme, and the concentrations of substrate/inhibitor
affecting its activity.56 Cell signaling coordinates metabolic pathways by sensing fuel
depletion or gain and transmitting information through signaling networks. This can be
observed by the integration of these pathways as a cellular response to extracellular
ligands or growth factors.38 The primary role of growth factors is to maintain
mitochondrial homeostasis and cell growth by regulation of glucose uptake and
metabolism in the body.57
The metabolic demands of a cell are dependent upon its location and environment.57
For example, immune cells go through cycles of extended inactivity and then rapid
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multiplication when roused.57 For this to happen, these cells must transition from a low
energy basal state of nutrient uptake to a state of high activity and nutrient absorption
with anabolic activity activated in such a way as to suit rapid growth and division.58
Conversely, cardiac muscle cells require large amounts of energy and do not multiply,
which is why they rely on oxidative phosphorylation to meet these ATP energy
demands.57,59 Liver cells regulate blood chemistry and therefore need adaptability to
make glucose, amino acids, macromolecules, recycle byproducts from other metabolic
pathways, and excrete waste.57,60
Glucose metabolism consists of the biochemical processes that are needed to utilize
glucose for energy such as glycolysis, gluconeogenesis, glycogenolysis, the pentose
phosphate pathway, citric acid cycle, and the electron transport system. Digestion breaks
down the complex carbohydrates that we eat into fructose, galactose, and primarily
glucose. These soluble simple sugars can be transported across the intestinal wall and
into the circulatory system where fructose and galactose undergo additional steps for
conversion to intermediary forms that enter the glycolytic pathway to produce energy.
Glucose is the most readily available form of energy for the body. Glucose travels to the
liver where it is either passes through into the circulatory system or stored as glycogen if
in excess. Insulin signals the uptake of glucose in insulin sensitive peripheral tissues
such skeletal muscle tissue; it promotes glycogenesis in the liver, and stops glucagon
secretion in pancreatic alpha cells.61 The discovery of additional glucoregulatory
hormones that influence glucose homeostasis such as amylin and glucagon like peptide-1
(GLP-1) allowed researchers to better understand how multifaceted the regulation of
glucose is.61 Researchers investigated the hormone glucagon, followed by amylin, and
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then GLP-1.61 They found that glucagon was part of glucose metabolism, amylin was
secreted by pancreatic alpha cells and complemented insulin, and that GLP-1 was a gut
hormone.61 Glucoregulatory hormones maintain glucose concentration within a narrow
range in the blood.61 Inadequate glucoregulatory control impacts aging and susceptibility
to type 2 diabetes, which is why targeting glucose metabolism is a way to improve the
quality of life and increase longevity. Prediabetes is a state of hyperglycemia where
glycemic parameters above normal but below the diabetic thereshold.62 It is an at-risk
state for the development of diabetes.62 The World Health Organization (WHO) has
defined prediabetes as a state of intermediate hyperglycemia using two specific
parameters, impaired fasting glucose (IFG) defined as fasting plasma glucose (FPG) of
6.1-6.9 mmol/L (110 to 125 mg/dL) and impaired glucose tolerance (IGT) defined as 2 h
plasma glucose of 7.8-11.0 mmol/L (140-200 mg/dL) after ingestion of 75 g of oral
glucose load or a combination of the two based on a 2 h oral glucose tolerance test
(OGTT).63 The American Diabetes Association (ADA), on the other hand has the same
cut-off value for IGT (140-200 mg/dL) but has a lower cut-off value for IFG (100-125
mg/dL) and has additional hemoglobin A1c (HbA1c) based criteria of a level of 5.7% to
6.4% for the definition of prediabetes.64 An increased risk of chronic kidney disease,
early neuropathy, retinopathy, and macrovascular disease are associated with
prediabetes.65–77 The complex cellular and molecular mechanisms responsible for
triggering prolonged elevated glucose levels in the body are not completely understood.
Aging is also characterized by metabolic oxidative stress a process influenced by
glucose metabolism. The Free Radical/Oxidative Stress Theory on Aging states that the
production of free radicals and oxidative species during cellular respiration damages
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proteins, lipids, and DNA; thus increasing the aging process and risk of disease.78
Oxidative stress occurs when the balance between prooxidants and antioxidants is
disrupted.79 The mitochondria couples with glucose metabolism to secrete insulin
through insulin exocytosis.80 Export of ATP to the cytosolic compartment promotes the
closure of ATP-sensitive K+ channels (KATP-channel) on the plasma membrane and, as
a consequence, depolarization of the cell.81 This leads to Ca2+ influx through voltagegated Ca2+ channels and a rise in cytosolic Ca2+ concentrations, the main and necessary
signal for exocytosis of insulin.82 Reactive oxidative species (ROS) can impair beta cell
function by attacking insulin secreting cells which in turn inactivates the mitochondria
consequently halting transduction signals normally coupled to glucose metabolism and
insulin secretion.83,84 A study comparing cellular metabolism and oxidative stress among
mammals and birds discovered that oxidative stress parameters most correlate with aging
in mammals.85
Glucose metabolism is part of what is necessary to maintain biological functioning,
yet it plays a significant role in different facets of human health. For instance, if glucose
levels in the body go unregulated a person can experience a number of ailments including
neuropathy, cardiovascular disease, stroke, and blindness. From nutrition to energy
maintenance to aging to illness and disease, glucose metabolism contributes to our
quality of life and overall wellness which why it is vital to understanding how biological
form fits function and how our processes work together to conserve our existence on
earth.
As obesity and diabetes become an ever-increasing problem, the role that insulin
resistance plays in this epidemic will gain more attention.86 Understanding how insulin
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affects morbidity by its involvement in many different physiological processes such as
synthesis and secretion and its resulting effects on the molecular and macro level of life
will give scientists and medical professionals a better means of combating illnesses and
improving mortality.
Insulin is secreted by the beta cells of pancreatic islets in response to changing
blood glucose levels in the body. As blood glucose levels rise, insulin is secreted into the
bloodstream by pancreatic islets.87 Insulin stimulates glucose uptake into fat and muscle
and promotes storage of glucose as intracellular triglycerides in adipose tissue and
glycogen in the liver and muscle.87 In addition, insulin inhibits the production and
release of glucose in the liver by gluconeogenesis and glycogenoloysis.87 Insulin
secretion takes part in regulation of carbohydrate, protein, and lipid metabolism and also
promotes cell division and growth through mitogenic effects.88 In order for growth
factors to stimulate mitogenesis, the induction of mitosis, they must activate the Ras-RafMap kinase signaling pathway. This pathway transduces signals from the extracellular
environment to the cell nucleus where genes are activated for cell growth, division, and
differentiation.89 Insulin mediates its actions by binding to insulin receptors.88 Insulin
receptors and IGF-1 receptors are part of the tyrosine kinase family and are structurally
homologous.90 These receptors are involved in signaling cascades that participate in
mitogenesis.90
The discovery of insulin and its role in metabolism has been critical to medical
research and science. Two German scientists in the late 1800s discovered insulin by
performing pancreatectomies on mice, which resulted in the mice acquiring diabetes.91
These scientist assumed that whatever was being secreted by the pancreas controlled
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metabolism.88 Around 1921, insulin was isolated and available for pharmaceutical
administration.88 This medication was given to diabetic dogs’ that had undergone
pancreatectomies.88 Upon administration of insulin, the dogs blood glucose levels
lowered. Later, insulin was administered to an adolescent child who had diabetic
symptoms, which were reversed after delivery of the medication.88 Further research has
to be carried out to determine what is going on during insulin secretory dysfunction and
insulin resistance during the development of diabetes and how these factors interact with
one another during the development of the disease to cause metabolic distortions.92
Insulin secretion is dependent on several factors such as insulin release from
secretory granules, transcription, translation, post-translational modifications in the Golgi
apparatus, and beta cell mass and differentiation.88,93 The insulin gene secretes the
precursor, preproinsulin, which is translocated from the cytosol across the endoplasmic
reticulum (ER) into the lumen by cytosolic ribonucleoproteins.94 During this
translocation, a single peptide is removed from preproinsulin to form proinsulin.95
Proinsulin undergoes folding and formation of three disulfide bonds to form a threedimensional conformation.96 Proinsulin is transported from the ER to the Golgi
apparatus where it enters immature secretory vesicles and is cleaved to yield insulin and
C-peptide.94 Insulin and C-peptide are stored in these vesicles until secretion along with
amylin and other less prominent beta cell secretory products.97,98
Insulin accumulates in the presence of nutrients and decreases in their absence.94
Beta cells quickly respond to cellular signals primarily because of transcriptional
regulation.94 Discrete elements within the promoter region of the insulin gene determine
the localization of insulin in beta cells and serve as binding sites for several beta cell
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transcription factors to regulate insulin gene expression.99 Beta cells increase protein
translation in response to nutrients.100 The release of insulin from secretory granules in
beta cells is communicated to the nucleus, which provides a positive feedback
mechanism to initiate insulin translation for maintaining a stored amount of insulin.94 In
addition to transcriptional regulation, insulin production is also dependent on immediate
environmental triggers that can regulate the speed of insulin translation.94
Beta cells sense changes in plasma glucose concentrations by clustering into islets
that are connected to the vasculature.94 Islets form a dense network with small blood
vessels and receive ten times the amount of blood than cells surrounding the exocrine
regions.94 Capillaries around the islets exchange nutrients with the surrounding tissues
and also have pores that allow rapid insulin diffusion into cells.101
Certain amino acid combinations at physiological concentrations or higher can
affect glucose stimulated insulin secretion (GSIS).102 For example, leucine along with
glutamine can stimulate insulin secretion from beta cells.103 Leucine can activate
glutamate dehydrogenase, which converts glutamate to α-ketoglutarate.94 Glutamine,
after conversion to glutamate in the cytosol by glutaminase, can alter the citric acid cycle
(TCA) by way of α-ketoglutarate resulting in energy production by generation of ATP
thereby enhancing insulin secretion.102
Dietary proteins are broken down into amino acids which are released from
intestinal epithelial cells in conjunction with glucose, thereby stimulating insulin
secretion leading to protein synthesis and the transport of amino acids to target tissues
like skeletal muscle.104 Glycogen synthesis in skeletal muscle accounts for the majority
of insulin stimulated glucose disposal in the body.105 L-glutamine and L-alanine are the
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most prominent amino acids in the blood that regulate insulin secretion followed by
branched chain amino acids.106 A study found that elevated amino acid levels to
postprandial concentrations caused insulin resistance by directly inhibiting muscle
glucose transport or phosphorylation following a reduction in the rate of glycogen
synthesis.107
During the fasting period, proteins in the skeletal muscle are catabolized and amino
acids are then metabolized to generate energy. Free amino acids, including alanine and
glutamine are released into the blood and serve as glucagon secretagogues. This results
in increased plasma glucose levels which triggers insulin secretion. Gastric inhibitory
peptide (GIP) and glucagon-like peptide 1 (GLP) are incretin hormones secreted from the
gastrointestinal tract. Ingestion of glucose and amino acids in the gut stimulates secretion
of these hormones from K-cells and L-cells. These hormones then bind to receptors on
beta cells and change GSIS.108–110 Leptin is secreted from adipocytes and is known to
influence action in fat and liver cells.111,112 Leptin has an inhibitory effect on insulin and
is associated with hyperinsulinemia in mice and humans.111,112 Plasma free fatty acids are
increased in obesity because expanded adipose tissue leads to excessive release of free
fatty acids.113,114 Although it is not entirely clear how obesity promotes insulin
resistance and type 2 diabetes, elevated plasma levels of free fatty acids have been found
to play a major role in this propensity. Free fatty acids promote insulin secretion to
compensate for the need of increased insulin as a result of insulin resistance in type 2
diabetes.115–117 However, this only occurs during short term free fatty acid exposure.117
Prolonged free fatty acid exposure decreases GSIS.118 Although the mechanisms behind
free fatty acid induced decrease in beta cell function is not fully understood, oxidative
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stress resulting from the breakdown of free fatty acids and the activity of the enzymes
involved could be a potential cause since beta cells have low antioxidant defenses.119,120
Beta cells’ exposure to an abnormally large amount of free fatty acids induces
lipoapoptosis.121,122
Glucose is the primary stimulus for insulin release in some organisms because it is
the main food source and accumulates quickly after ingestion.94 In humans, blood
glucose is affected more by glucose rather than consuming the same amount of fat or
protein.101 Neurons require glucose for fuel but other cells can use alternative fuel
sources in times when glucose is not available.101 Glucose is phosphorylated by the rate
limiting enzyme glucokinase after entering beta cells; glucokinase has a low affinity for
glucose than other hexokinases and it is not inhibited by its product.94 This makes it rate
limiting and a significant glucose sensor.101 Insulin resistance occurs when normal or
elevated insulin levels produce a reduced biological response, which is known as
impaired sensitivity to insulin-mediated glucose disposal.114,123 This impaired biological
response of insulin to target tissues occurs mainly in the liver, skeletal muscle, and
adipose tissue. Hyperinsulinemia is also a consequence of insulin resistance and takes
place when pancreatic beta cell secretion increases to maintain normal blood glucose
levels in peripheral tissues such as the muscle and liver.88 Disproportionate
hyperinsulinemia was discovered in the 1960s when validated assays were used to
determine plasma insulin concentrations leading to the recognition of insulin resistance.92
Insulin resistance is thought to precede type 2 diabetes by 10 to 15 years.124 Insulin
resistance syndrome is the number of abnormalities and physical issues that people with
insulin resistance have such as hyperglycemia, hypertension, dyslipidemia, visceral
15

adiposity, hyperglycemia, elevated inflammatory markers, endothelial dysfunction, and
thrombophilia.88,124 Metabolic syndrome is the clustering of such conditions that
increases a person’s morbidity towards developing heart disease due to insulin
resistance.88,124
Type 1 and type 2 diabetes are both associated with progressive beta cell
destruction, occurring by apoptosis. Insulin secretion involves the fusion of insulin
granules with the plasma membrane and exocytosis of cellular content. A small fraction
of the granules is available for rapid release of insulin when triggered by glucose.125 The
majority of the granules serve as a backup reserve. Glucolipotoxicity is the harmful
effects that occur to the beta cell when in the presence of elevated glucose and lipid
concentration in the blood. Beta cells do not turnover rapidly and have and low
proliferation rate in comparison to those that are apoptotic. Conversely, the body
increases proliferation in obese and insulin resistant individuals.126–129

LEW.1WR1 and LEW/SsNHsd Rat Models
Animal models are needed to complement human studies because these models
provide researchers with a broad measure of how experimental methods will work on
living anatomy and physiology. From there, basic observations are gathered and
developed to continue the study further on humans. The LEW.1WR1 rat model is
susceptible to autoimmune disorders such as diabetes and arthritis.130 The major
histocompatibility complex (MHC) locus consists of many genes that participate in
immune surveillance against cancer and infectious diseases.131 The human MHC is also
called the human leukocyte antigen (HLA) complex.132 The human leukocyte antigen F
locus adjacent transcript 10 (FAT10) gene is located in the distal human Class I region of
16

the MHC complex.131,133 Non-Class I genes in this region, such as FAT10, are partly
interspersed with the Class I genes and are diverse in structure and function, belonging to
a variety of families.131–133 FAT10 is a susceptibility gene for virus triggered
autoimmune diabetes.134 It is a ubiquitin like modifier that is encoded in the major
histocompatibility complex (MHC). FAT10 encodes a diubiquitin-like protein containing
two head-to-tail ubiquitin like domains.131 Ubiquitin is a small highly conserved protein
found in all studied eukaryotic cells that is pivotal in regulating degradation for many
different types of protein.131 Regulation is controlled by a covalent binding of ubiquitin
to the target protein.131 Other genes that contain structural motifs related to ubiquitin,
such as FAT10, have been discovered.131 The ubiquitin proteasome pathway is the main
system used for the targeted degradation of intracellular proteins.135 FAT10 mRNA is
expressed in organs where B- and T- cells develop into mature lymphocytes, suggesting
that it plays an important role in lymphocyte maturation.131 In addition, the expression
of FAT10 may be transient and labile and regulated at the transcriptional, translational,
and posttranslational level by cytokines such as INF-γ and TNF-α.136–138 FAT10 has
been implicated in immune response and cancer development.139 FAT10 overexpression
proliferated tumor growth in cancer cells.139 Also, FAT10 was found to activate nuclear
factor-κB (NFκB) which, in turn, upregulates chemokine receptors CXCR4 and
CXCR7.139
FAT10 controls various cell functions such as apoptosis, cell cycle, and immune
responses by covalently modifying its target proteins.140,141 The tumor suppressor p53 is
a target substrate of FAT10.140,142 Under inflammatory conditions FAT10 overexpression
represses p53 transcriptional activity increasing tumor growth and tumerogenesis.140
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FAT10 tags lipids for protein degradation during beta oxidation and counteracts the
tumor suppressor p53.140,143 Unlike other ubiquitin like modifiers, FAT10 is synthesized
with a free diglycine motif at its C terminus that is used for its activation by a specific E1
enzyme (E1-L2) and subsequent conjugation to its substrates.143–145 Fusion of FAT10 to
the N terminus of target proteins causes rapid degradation.146 FAT10ylation is a posttranslational modification yielding a covalent isopeptide bond between FAT10 and a
target protein.145,147,148 FAT10ylation of downstream proteins was hypothesized to target
them for proteasomal degradation.143,145 FAT10 is overexpressed in various cancers
including liver, colon, gastrointestinal, and a range of gynecological turmors.149 FAT10
is primarily induced by inflammatory cytokines such as TNF-α, but the presence of
secondary cytokines, such as INF-γ can increase FAT10 expression further.150 A study
involving FAT10 knockout mice implicated FAT10 as a metabolic regulator with a role
in aging.151 The mice also had increased lifespan, reduced adiposity, lower circulating
blood glucose and insulin levels, and heightened insulin sensitivity.151
Experimentation has taken place influencing LEW.1WR1 rat’s immune response
by immunological innate or adaptive perturbation; thus, exacerbating the probability of
the model acquiring autoimmune disease.130 Studies performed on the biobreeding
diabetes-prone rat (BBDP) showed that its diabetes susceptibility was related to MHC
and non MHC- linked genetic loci that are orthologous to human genome-wide
association studies (GWAS) loci.152 Iddm14 was found to play an important part in the
autoimmune susceptibility of this rat to disease.153 The Iddm14 locus in rats is a powerful
determinant of disease penetrance in the LEW.1WR1 rat due to viral infection.153 Locus
Iddm37 enhances penetrance of Iddm14. The Iddm37 region contains the diubiquitin
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gene also known as FAT10 that is homologous to mouse and human diabetes promoting
intervals.154,155 Understanding the genetic contributors to disease susceptibility in the
LEW.1WR1 rat will help scientists figure out what is occurring genetically in humans as
they become diseased.
Obesity-associated adipose tissue inflammation was formerly thought to be
mediated by macrophages infiltrating metabolic tissues such as the liver and visceral
adipose tissue.156,157 Just like macrophages, B- and T- cells infiltrate the visceral adipose
tissue of obese humans and mice to a similar extent and with comparable inflammatory
responses that occur during insulin resistance.158 Alterations in some subclasses of
circulating IgG’s are seen during obesity related insulin resistance.158 Transfer of CD8+
T cells or high fat diet-induced IgG antibodies can aggravate insulin resistance without
affecting obesity while T- or B-cell depletion or genetic deficiency improves insulin
resistance in diet induced obese mice.158–161 Multiple tissues and organs such as the liver,
visceral adipose tissue, muscle, pancreas, cardiovascular tissue, and the hypothalamus are
affected by the low grade inflammation that is associated with obesity.162
The LEW/SsNHsd rat model comes from the inbred Lewis rat strain, which is
known for being susceptible to the development of autoimmune disease.163 Lewis rats
have high levels of inflammatory chemokines such as MCP-1, RANTES, and IL-1β upon
viral infection of River Valley Fever.164 This inflammatory response is a biomarker
signaling immunological compromise that can be used to evaluate infection or disease.164
Evidence has shown that some lines of Lewis rats develop autoimmune disorders faster
than others due to differences in the hypothalamus-pituitary-adrenal system.165 Using
this information, a study compared the autoimmune disease susceptibility of the
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LEW/SsNHsd rat model to the LEW/HANRijHsd rat model and found minimal
differences in the functioning of the hypothalamus-pituitary-adrenal system between the
two groups.165 Although the two rat models had significantly dissimilar behavioral
patterns.165 The behavioral and endocrine response of the LEW/SsNHsd rat model to an
environmental challenge was compared to a Fischer rat strain.165 The rat groups were
exposed to stress environments and their responses were measured.165 Although stress
responses varied among rat models and sex, the study provided further evidence that
environmental perturbation creates distinct emotional states that can be linked to certain
neural pathways.165 The LEW/SsNHsd rat became a model for sporadic Alzheimer’s
disease associated with obesity-related peripheral metabolic abnormalities by
intracerebroventricular administration of streptozotocin.166 This induction increased the
rat model’s food intake, body weight, blood levels of insulin and leptin without altering
glucose homeostasis.166
The relationship between aging, obesity, and insulin resistance exists and the
mechanisms by which one affects the other are still being investigated. Insulin resistance
is a condition where normal amounts of insulin fail to maintain normal blood glucose
levels because of the decreased responsiveness of glucose uptake in muscle, inhibition of
gluconeogenesis in the liver, and inhibition of lipolysis.167 The LEW.1WR1 rat model is
optimal for studying this because it has an overexpression of FAT10, which has been
implicated in aging and increased adiposity. Longevity is inversely associated with
increased adiposity in humans and animal models.168,169 FAT10 knockout mice had
elevated IL-10 which suppresses inflammation and enhances whole body insulin
sensitivity by inhibiting the signals of proinflammatory cytokines, IKK/NF-κB signaling,
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and endoplasmic reticulum stress which are all pathways that play a role in cell
survival.151,170,171 FAT10 target proteins and interacting biomolecules have roles in
energy sensing, nutrient and bile acid metabolism, and insulin-, PI3K/ Akt/mTOR-, and
cAMP- dependent signaling as well as NF-κB– dependent gene expression.172–174
Determining FAT10’s role in aging, obesity, and insulin resistance will help to better
understand the mechanism by which one affects the other.
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Chapter 2

Materials and Methods

2.1 Acclimation of Rats to the Environment
The LEW.1WR1 (1WR1) rats arrived from Biomere (Worcester, MA). The
LEW/SsNHsd (SsNHsd) rats arrived from Envigo (Indianapolis, IN). There were 14
animals for each type of rat model totaling 28 rats in all. Upon arrival, the animals were
housed at the University of Alabama in Huntsville (UAH) Vivarium and maintained with
a 12 hour light-dark cycle. The animals were caged in groups of 3 and 4 and were
acclimated to the environment a week before testing began. During this time, the animals
were given water and fed a standard rat chow diet. In addition, they were allowed to
roam their cages and interact with their cage mates freely. Food was replenished as
needed and the cages and corncob bedding were changed on Mondays and Fridays. The
bedding was replaced with Sani-Chips, purchased from Envigo, because the rats were
pushing the corncob bedding towards the outer perimeter of their cages and residing on
the cage floor. Because of the staggered arrival times of the two rat groups, the 1WR1 rat
group started testing a week before the SsNHsd rat group. Both rat groups were 5 to 6
weeks old upon arrival. The length of the entire study was 12 weeks, with testing
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occurring at the zero time point, after the acclimation period. The experimental protocol
was approved by University of Alabama in Huntsville Institutional Animal Care and Use
Committee.

2.2 Glucose Tolerance Tests
A glucose tolerance test (GTT) was performed at zero and eight weeks into the
study. The glucometer used to measure blood glucose values over the duration of each
GTT was an Alpha Traks 2 meter by Zoetis (Parsippany, NJ). An initial baseline blood
glucose value was taken by tail prick before the animals were intraperitoneal (IP) injected
with a bolus of 50% dextrose solution. After the IP injection, subsequent glucose values
were obtained by tail prick and recorded in 30 minute increments for 90 minutes. The
50% dextrose solution was made using glucose (MP Biomedical) and 10x PhosphateBuffered Saline (PBS), which was obtained from Thermo Fisher Scientific (Waltham,
MA). The amount of 50% dextrose solution given to each rat was based on its body mass
with every animal receiving 2 g of glucose per kg of body mass multiplied by 2 mL of
50% dextrose solution per g of glucose.

2.2.1 Baseline Glucose Tolerance Test
The baseline GTT started the testing phase of the study and was designated as the
zero time point. The 1WR1 rat group was tested in comparison to the SsNHsd rat group
in order to determine if any significant differences in blood glucose levels existed
between the two rat groups. The 1WR1 and SsNHsd rat groups were 6 to 7 weeks old
when the baseline GTT was carried out. For the baseline GTT, the animals were weighed
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and then fasted for 4 hours prior to the start of the test. After the baseline GTT, the rats
stopped consuming the standard rat chow and were put on a special diet. The two rat
groups, 1WR1 and SsNHsd, were separated into a high fat diet (HFD) group and control
group. Seven rats were assigned to each rat group and classified as follows: 1WR1 HFD,
1WR1 Control, SsNHsd HFD, and SsNHsd Control. Table 2.1 lists the rat grouping.
Each of the four rat groups had 2 cages that contained 3 rats a piece and 1 cage that
contained 4 rats. The two HFD rat groups consumed rat food that contained 45% fat
(D12451 45 kcal %) and the two control groups consumed food that contained 10% fat
(D12450J 10 kcal %). The special diet food was purchased from Research Diets (New
Brunswick, NJ). The four rat groups were weighed and given fresh food every Monday
and Friday. Food was replenished, outside of those days, as it was consumed by the
animals.
Table 2.1. Rat Numbering and Grouping
Rat Numbering and Grouping
Rat Model Rat Number Experimental Group
1WR1
Rat 1-7
Control
1WR1
Rat 8-14
HFD
SsNHsd
Rat 15-20
Control
SsNHsd
Rat 21-28
HFD

2.2.2 Eight Week Glucose Tolerance Test
The eight week GTT occurred eight weeks into consumption of the special diet
and was designated as the eight week time point of the study. During this period, the
1WR1 and SsNHsd rat groups were 14 to15 weeks old. The animals were weighed and
then fasted for 8 hours prior to the start of the eight week GTT.
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2.3 Four Week Insulin Tolerance Test
An insulin tolerance test (ITT) was performed four weeks into the rat groups
being on the special diet. The 1WR1 and SsNHsd rat groups were 10 to 11 weeks old at
this time. Prior to the start of the test, the rat groups were weighed and then fasted for
four hours. After fasting, the rat groups had their baseline blood glucose values taken by
tail prick using the Alpha Traks 2 glucometer. Following the baseline blood glucose
reading, each rat was IP injected with insulin and their blood glucose values were taken
by tail prick and then recorded in 30 minute increments for 90 minutes. The insulin
solution was prepared using Humulin (Patterson Veterinary Supply) and PBS. The
Humulin insulin had a concentration of 100 units of insulin/mL. A 1:10 insulin solution
was made by diluting the Humulin insulin with PBS. The rat groups received 0.75 unit of
insulin/kg of body mass. This was calculated by multiplying the rat body mass by 0.75
unit of insulin/kg of body mass divided by 1 unit of insulin/mL of solution.

2.4 Ten Week Sacrifice and Harvest
Prior to sacrifice the animals were weighed and then fasted for 8 hours. The
animals were exsanguinated at 10 weeks into testing. The 1WR1 and SsNHsd rat groups
were 16-17 weeks old.

Figure 2.4. Testing Timeline and Rat Group Ages
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2.4.1 Blood Marker Measurements
Before sacrifice, terminal fasting blood glucose levels were measured for the rat
groups using an Alpha Tracks 2 glucometer. Upon sacrifice, blood was taken from each
rat, collected in 15 mL conical tubes, and allowed to clot on a rack for exactly 15
minutes. Immediately following this time period, the blood in the conical tubes was
centrifuged for 10 minutes at 1000 x g at 4°C to separate the blood serum from red blood
cells and clotting factors. The blood serum, the clear and colorless layer in the conical
tube, was collected using a micropipette and aliquoted into 1 mL eppendorf tubes. The
Eppendorf tubes were centrifuged for 15 minutes in an Eppendorf centrifuge to further
separate the serum from any remaining red blood cells and clotting factors. In instances
where the serum was not clear and colorless after the Eppendorf centrifugation, the serum
layer was collected from the Eppendorf tube and centrifuged again. After the serum was
completely separated, it was portioned off with 100 μL designated for the metabolic
panel, 100 μL for the cytokine and chemokine array, and two 500 μL portions for serum
metabolomic analysis. Blood plasma was also collected in heparinized plasma tubes for
the metabolic and cytokine and chemokine arrays. The blood plasma was inverted in
heparinized plasma tubes several times and then centrifuged at 1000 x g for 10 minutes.
The supernatant was collected in eppendorf tubes and centrifuged for 15 minutes using an
Eppendorf centrifuge. The supernatant was removed and 100 μL was collected for the
metabolic panel and 100 μL was collected for the cytokine and chemokine array. Further
sample preparation, for the serum and blood plasma samples being used for the metabolic
array, required the addition of inhibitors and PBS according to Eve Technologies
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protocol (Ontario, Canada). The multiplex analysis was performed by Eve Technologies.
The data was representative of Millipore MILLIPLEX Metabolic 11-Plex Array Assay
Kit and BioPlex 200 Cytokine Array Assay Kit.

2.4.2 Islet Isolation and Histopathology
During harvest the pancreas from each rat was collected. Half of the pancreata
were used for islet isolation and the other half were used for histopathological
examination. The rats that were used for islet isolation were the 1WR1 control rat 1-3,
1WR1 HFD rat 8-10, SsNHsd control rat 18, 19, and 21, and SsNHsd HFD rat 26-28.
The islets for rat 20 were disposed of accidentally. As a result, SsNHsd control rat 18
was designated for islet isolation. The islets were isolated by collagenase digestion and
handpicked under a stereomicroscope. 1WR1 control rat 4-7, 1WR1 HFD rat 11-14,
SsNHsd control rat 15-17, and SsNHsd HFD rat 22-25 were used for histopathological
examination. Rat pancreata were harvested, put in cartridges, and then fixed in 10%
Neutral Buffered Formulin at room temperature for 24 hours. After fixation, the
cartridges were transferred to plastic storage containers, submerged in 70% ethanol, and
immediately shipped to Histowiz (Brooklyn, New York). The formalin-fixed, paraffinembedded pancreatic tissues of each animal were sectioned (4 μm) and stained against
insulin, and digitized as a slide image. After receiving digitized images of the pancreata,
they were scored based on histological appearance. Pancreata were graded according to
size on a scale of extra small (xs), small (s), medium (m), and large (l) on a magnification
or 4x (500μ)
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2.5 Statistical Analysis
Statistical analysis was carried out using GraphPad Prism 7.04 (La Jolla,
California). Area under the curve, One-way ANOVA followed by the Tukey test, and
graphing were done using this software. Significance for statistical analysis is listed in
the legend under each figure in the results section.

2.6 Nuclear Magnetic Resonance Spectroscopy (NMR) Analysis
A serum protocol was developed so that it could be used for future analysis of the
serum collected at sacrifice. The serum protocol was produced in order to isolate certain
metabolites of interest while extracting any unwanted proteins that interfere with the
NMR signals of the metabolites of interest. The serum protocol was developed from a
paper written by John Sheedy.

In this paper, six protocols were used to analyze

metabolites in an artificial biofluid. The artificial biofluid contained common metabolites
and 40 mg/mL of bovine serum albumin (BSA). The six protocols from the paper were
as follows:
Protocol A. The sample was centrifuged at 3000 x g at 4°C for 10 minutes. 250 μL of the
sample was removed and diluted with 250 μL of 200 mM sodium phosphate buffer in
deuterium oxide (normalized to pH 7 using deuterium chloride), followed by the addition
of 50 μL of deuterium oxide containing 0.5 mM DSS and 0.2% (w/v) sodium azide and
analyzed on the NMR.
Protocol B. 1 mL of sample was subjected to ultrafiltration on a 3 kDa centrifugal
filtration device that was washed five times with 200 mM sodium phosphate buffer.
After centrifugation at 3000 x g at 4°C for 10 minutes, 250 μL of the filtrate was mixed
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with 250 μL of 200 mM sodium phosphate buffer in deuterium oxide (normalized to pH
7 using deuterium chloride) and 50 μL of deuterium oxide containing 5 mM DSS and
0.2% (w/v) sodium azide and analyzed on the NMR.
Protocol C. 500 μL of sample was chilled on ice and directly diluted with 300 μL of
chilled deuterated chloroform and 200 μL of chilled deuterated methanol and was
incubated for 10 minutes on ice. The biphasic mixture was centrifuged at 3000 x g at 4°C
for 10 minutes. 250 μL of the upper aqueous phase was mixed with 250 μL of 200 mM
sodium phosphate buffer in deuterium oxide (buffered to pH 7 using deuterium chloride)
and 50 μL of deuterium oxide containing 5 mM DSS and 0.2% (w/v) sodium azide and
analyzed on the NMR. Protocol C was the basis from which protocol development for
this study took place because it was the most optimized in the paper written by John
Sheedy.
Protocol D. 500 μL of the sample was mixed with 300 μL of ice-cold chloroform and 200
μL of ice-cold methanol and then incubated on ice for 10 minutes. The biphasic mixture
was centrifuged at 3000 x g at 4°C for 10 minutes. 250 μL of the upper aqueous phase
was dried under a stream of nitrogen. The sample was resuspended in 250 μL of
deuterium oxide and 250 μL of 200 mM sodium phosphate buffer in deuterium oxide
(buffered to pH 7 using deuterium chloride), followed by the addition 50 μL of deuterium
oxide containing 5 mM DSS and 0.2% (w/v) sodium azide and analyzed on the NMR.
Protocols E and F. Both protocols were identical to Protocol D except the upper aqueous
phase was dried by lyophilization in Protocol E or speed vacuum in Protocol F.

47

2.6.1 NMR Analysis of Artificial Fluid with and without BSA
The artificial fluid prepared during protocol development was made using the Cold
Spring Harbor potassium phosphate buffer protocol modified to make a working buffer
solution at pH 7.0 from stock standards that were ten times more concentrated than the
working buffer solution. An artificial fluid containing 1.67 mM aspartic acid, glutamic
acid, glucose, and alanine was made in 10 mM potassium phosphate buffer.

This

artificial fluid was designated as sample 1. Another artificial fluid prepared in 10 mM
potassium phosphate buffer containing 0.5 mM BSA and 1.67 mM aspartic acid,
glutamic acid, glucose, and alanine was made. This artificial fluid was called sample 2.
Both artificial fluids were made from 10 mM stock solutions of glutamic acid, alanine,
aspartic acid, and glucose. In sample 1, 150 μL of each stock solution was added to a 5
mm NMR tube. 150 μL of 5 mM sodium trimethylsilylpropanesulfonate (DSS) with
0.1% (w/v) sodium azide in 100% D2O was added to the NMR tube. Sample 1 was
analyzed. For sample 2, the BSA solution was made by weighing and transferring it into
a beaker, adding 10 mM potassium phosphate buffer, and then letting the solution stand
to dissolve the BSA. Palmitic acid and cholesterol were added to the BSA solution.
However, they did not dissolve due to their limited solubility in water. As a result, even a
miniscule amount of palmitic acid and cholesterol was not a small enough quantity to
overcome their lack of solubility in solution.
BSA, potassium phosphate dibasic, potassium phosphate monobasic, aspartic acid,
and dextrose monohydrate (glucose) were purchased from Thermo Fisher Scientific.
Glutamic acid and alanine were bought from Sigma Aldrich. Aspartic acid and palmitic
acid were purchased from Acros Organics. Deuterated chloroform and methanol were
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obtained from Cambridge Isotope Laboratory, Inc. Water Presaturation (PRESAT) and
Nuclear Overhauser Effect Spectroscopy (NOESY)

1

H NMR experiments were

performed on a 500 MHz instrument at 25 °C.

Figure 2.6.1.1. 1.6 mM Artificial Fluid Sample 1 without BSA PRESAT 1H NMR
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Figure 2.6.1.2. 1.6 mM Artificial Fluid with BSA PRESEAT 1H NMR

2.6.2 Analysis of Artificial Fluid with Palmitic Acid and Cholesterol
Palmitic acid and cholesterol did not dissolve in the 3 mM BSA stock solution that
was used to make the artificial fluid in section 2.6.1. The concentration of palmitic acid
and cholesterol in the 3 mM BSA stock solution was 10 mM, which was decreased by a
third to aid in solubility. The same prep listed in section 2.6.1 was carried out, weighing
a third of palmitic acid and cholesterol into the 3 mM BSA stock solution in order to
dissolve them both. After this attempt, palmitic acid and cholesterol did not dissolve in
the BSA. This artificial fluid was analyzed on the NMR using PRESAT and NOESY.
The NOESY was sample 1 and PRESAT was sample 2.
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Figure 2.6.2.1. 10 mM Artificial Fluid with BSA PRESAT 1H NMR
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Figure 2.6.2.2. 10 mM Artificial Fluid with BSA NOESY 1H NMR

2.6.3 Protocols A-F using the Artificial Fluid
PRESAT 1H NMR was used to analyze samples for the duration of the study. The
protocols A-F were carried out in the lab to see if results similar to the original
experiment, by John Sheedy and colleagues, could be obtained. The artificial fluid was
made containing glucose, aspartic acid, alanine, glutamic acid, and the BSA solution.
The BSA solution included the undissolved palmitic acid and cholesterol. None of the
protocols produced a flat baseline, which means that the BSA was not completely
extracted from the artificial fluid.
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Protocol A. 200 μL of 10 mM stock standards alanine, aspartic acid, glucose, glutamic
acid, and 3 mM BSA with palmitic acid and cholesterol were pipetted into a 15 mL
conical tube. An aliquot of this standard mixture was pipetted into an Eppendorf tube
and centrifuged at 3000 x g at 4°C for 10 minutes. 337.5 μL of the upper aqueous phase,
337.5 μL of 10 mM potassium phosphate buffer, and 75 μL of 5 mM DSS with 0.1%
(w/v) sodium azide in100% D2O was transferred into a 5 mm NMR tube and analyzed.
Protocol B. 200 μL of 10 mM stock standards alanine, aspartic acid, glucose, glutamic
acid and 3 mM BSA with palmitic acid and cholesterol were pipetted into a 15 mL
conical tube. 1 mL of the standard mixture was added to the ultrafiltration 3 kDa
centrifugal device and centrifuged down to 250 μL. Prior to centrifugation, the
centrifugal filtration device was pre washed with 10 mM potassium phosphate buffer.
The filtrate was diluted with what was filtered off of the sample to obtain a volume of
337.5 μL. 337.5 μL of the filtrate, 337.5 μL of 10 mM potassium phosphate buffer, and
75 μL of 5 mM DSS with 0.1% (w/v) sodium azide were transferred to a 5 mm NMR
tube and analyzed
Protocol C. 100 μL of 10 mM stock standards alanine, aspartic acid, glucose, glutamic
acid and 3 mM BSA with palmitic acid and cholesterol were pipetted into an eppendorf
tube and chilled on ice. The mixture was diluted with 300 μL of chilled deuterated
chloroform and 200 μL of chilled methanol and then it was incubated on ice for 10
minutes. The mixture was centrifuged at 3000 x g at 4°C for 10 minutes. 337.5 μL of the
upper aqueous phase, 337.5 μL of 10 mM potassium phosphate buffer, and 75 μL of 5
mM DSS with 0.1% (w/v) sodium azide was transferred to a 5 mm NMR tube and
analyzed.
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Protocol D. 100 μL of 10 mM stock standards alanine, aspartic acid, glucose, glutamic
acid and 3 mM BSA with palmitic acid and cholesterol were pipetted into an eppendorf
tube and mixed with 300 μL of ice-cold chloroform and 200 μL of ice-cold methanol.
The mixture was incubated on ice for 10 minutes and then centrifuged at 3000 x g at 4°C
for 10 minutes. 250 μL of the upper aqueous phase was dried using a speed vacuum
concentrator. The dried sample was resuspended in 337.5 μL of deuterium oxide and
combined with 337.5 μL of 10 mM potassium phosphate buffer which was added to a 5
mm NMR tube along with 75 μL of 5 mM DSS with 0.1% (w/v) sodium azide in 100%
D2O and then the solution was analyzed.
Protocol E. 100 μL of 10 mM stock standards alanine, aspartic acid, glucose, glutamic
acid and 3 mM BSA with palmitic acid and cholesterol were pipetted into an Eppendorf
tube and mixed with 300 μL of ice-cold chloroform and 200 μL of ice-cold methanol.
The mixture was incubated on ice for 10 minutes and then centrifuged at 3000 x g at 4°C
for 10 minutes. 250 μL of the upper aqueous phase was evaporated by using a speed
vacuum concentrator and then lyophilized overnight for 24 hours. The dried sample was
resuspended in 337.5 μL of deuterium oxide and transferred to a 5 mm NMR tube. 337.5
μL of 10 mM potassium phosphate buffer and 75 μL of 5 mM DSS with 0.1% (w/v)
sodium azide were added to the NMR tube and then the solution was analyzed.
Protocol F. 100 μL of 10 mM stock standards alanine, aspartic acid, glucose, glutamic
acid and 3 mM BSA with palmitic acid and cholesterol were pipetted into an Eppendorf
tube and mixed with 300 μL of ice-cold chloroform and 200 μL of ice-cold methanol.
The mixture was incubated on ice for 10 minutes then centrifuged at 3000 x g at 4°C for
10 minutes. 250 L of the upper aqueous phase was dried using a rotary evaporator. The
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dried sample was resuspended in 337.5 μL of deuterium oxide and transferred to a 5 mm
NMR tube. 337.5 μL of 10 mM potassium phosphate buffer and 75 μL of 5 mM DSS
with 0.1% (w/v) sodium azide in 100% D2O was added to the NMR tube and then the
artificial fluid was analyzed.

Figure 2.6.3.1. Protocol A using Artificial Fluid
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Figure 2.6.3.2. Protocol B using Artificial Fluid
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Figure 2.6.3.3. Protocol C using Artificial Fluid
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Figure 2.6.3.4. Protocol D using Artificial Fluid
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Figure 2.6.3.5. Protocol E using Artificial Fluid
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Figure 2.6.3.6. Protocol F using Artificial Fluid

2.6.4 Comparison of 10 mM standard solution to 1.6 mM standard solution
10 mM and 1.6 mM artificial fluids were made to compare the signal of each
peak in the NMR spectrum at different concentrations. 100 μL stock standards for
alanine, aspartic acid, glucose, and glutamic acid were made. To make the 10 mM
artificial fluid, 75 μL of each stock standard was added to a 5 mm NMR tube along with
150 μL of 5 mM DSS with 0.1% (w/v) sodium azide in 100% D2O. 300 μL of 10 mM
potassium phosphate buffer was also added to the 5 mm NMR tube. The 1.6 mM
artificial fluid was made by adding 7.5 μL of each 100 μL stock standard to another 5
mm NMR tube along with 150 μL of 5 mM DSS with 0.1% (w/v) sodium azide in 100%
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D2O and 570 μL of 10 mM potassium phosphate buffer. Refer to Figure 3.6.1.1 for the
1.6 mM artificial fluid without BSA PRESAT 1H NMR.

Figure 2.6.4. 10 mM Artificial Fluid without BSA PRESAT 1H NMR

2.6.5 Trials for Protocol C
Protocol C was prepared and followed as listed in section 3.6.3. Protocol C was
repeated several times, because it produced the highest recovery of metabolites in the
original paper written by John Sheedy. This was done in hopes that the replicated
protocol would produce similar results in the lab. The samples were analyzed on the
NMR and ran using a PRESAT 1H NMR. A flat baseline and peak resolution were not
observed.
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Figure 2.6.5.1. Protocol C Trial 1
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Figure 2.6.5.2. Protocol C Trial 5
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Figure 2.6.5.3. Protocol C Trial 6

2.6.6 Protocol C Modified to Include Intermittent Shaking during Incubation
Protocol C was modified in order to get a spectrum with a flat baseline. Protocol
C in section 2.6.3 was repeated for several samples. 100 μL of 10 mM stock standards
alanine, aspartic acid, glucose, glutamic acid and 3 mM BSA with palmitic acid and
cholesterol were pipetted into an Eppendorf tube and chilled on ice. The mixture was
diluted with 300 μL of chilled deuterated chloroform and 200 μL of chilled methanol
then it was incubated on ice for 10 minutes, shaking the Eppendorf every two minutes for
the duration of the incubation period. This process was repeated twice. The mixture was
centrifuged at 3000 x g at 4°C for 10 minutes. 341 μL of the upper aqueous phase, 260
μL of 10 mM potassium phosphate buffer, and 75 μL of 5 mM DSS with 0.1% (w/v)
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sodium azide in 100% D2O was transferred to a 5 mm NMR tube and analyzed. A flat
baseline was produced in the spectra. As a result, several more trials were carried out
with this modified protocol using NOESY for NMR analysis instead of PRESAT.

Figure 2.6.6.1. Modified Protocol C before Extraction

65

Figure 2.6.6.2. Modified Protocol C after Extraction
2.6.7 Spiked Samples to Determine Peak Assignments
Spiked samples for alanine, glutamic acid, glucose, and aspartic acid were made.
280 μL of the spiked standard and 105 μL of the other three standards were combined in
and 1.7 mL eppendorf tube. 420 μL of chilled chloroform and 280 μL of chilled
methanol were added to the eppendorf tube. The solution was incubated on ice for 10
minutes with intermittent shaking every two minutes. The sample solution was
centrifuged at 3000 x g at 4°C for 10 minutes. The upper aqueous phase was collected
and then the extraction was performed again. 341 μL of the upper phase, 280 μL of 10
mM potassium phosphate buffer, and 150 μL of DSS with 0.1% (w/v) sodium azide in
100% D2O was transferred to a 5 mm NMR tube and analyzed.
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Figure 2.6.7.1. Spiked Aspartic Acid Artificial Fluid
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Figure 2.6.7.2. Spiked Alanine Artificial Fluid
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Figure 2.6.7.3. Spiked Glucose Artificial Fluid
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Figure 2.6.7.4. Spiked Glutamic Acid Artificial Fluid

2.6.8. Metabolites Found in the Aqueous and Organic Phases of the Biphasic
Mixture
Attempts at altering the ratios of chloroform and methanol in modified Protocol C
in order to get complete recovery proved to be unsuccessful. As a result, careful
observation led to the discovery that the metabolites were in both the aqueous and
organic phases of the biphasic mixture. Modified Protocol C was carried out. 100 μL of
10 mM stock standard solutions of alanine, aspartic acid, glutamic acid, and glucose were
pipetted into an Eppendorf tube. The solution was diluted with 300 μL of chilled
deuterated chloroform and 200 μL of chilled methanol then the solution was incubated on
ice for 10 minutes and vortexed. The mixture was centrifuged at 3000 x g at 4°C for 10
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minutes. 600 μL of the organic lower phase, underneath both the upper aqueous phase
and pellet layer, was collected and transferred to a 5 mm NMR tube. 5 mM DSS with
0.1% (w/v) sodium azide in 100% D2O was added to the NMR tube and the mixture was
analyzed.

2.6.9 Sample Preparation Modifications to Recover Metabolites from Aqueous and
Organic Phases using a Syringe Filter
Sample Prep 1
Two different methods were used to recover the metabolites from the aqueous and
organic phases. In sample prep 1, 100 μL of 100 mM alanine, aspartic acid, glutamic
acid, and glucose stock solutions were pipetted into an Eppendorf tube. 100 μL of 3mM
BSA was added to the Eppendorf tube. The sample was chilled on ice until cool, 300 μL
of chilled chloroform and 200 μL of chilled methanol were added to the Eppendorf tube.
The mixture was vortexed for 15 seconds and the solution was incubated over ice for 10
minutes. The mixture was centrifuged at 15,000 x g at 4°C for 10 minutes. The aqueous
layer was collected. The remaining liquid was centrifuged again at 15,000 x g at 4°C for
10 minutes and the organic layer was collected. Both the aqueous and organic layers
were combined and then put on the concentrator to evaporate the liquid. The sample was
removed from the evaporator and diluted with 600 μL of 10 mM potassium phosphate
butter. The sample did not completely dissolve in solution. This solution along with 150
μL of 5 mM DSS with 0.1% (w/v) sodium azide in 100% D2O was added to an NMR
tube and the mixture was analyzed.
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Figure 2.6.9.1. Sample 1 without 0.2 μm Syringe Filter

Sample Prep 2
100 μL of 100 mM alanine, aspartic acid, glutamic acid, and glucose stock
solutions were pipetted into an Eppendorf tube. 100 μL of 3mM BSA was added to the
Eppendorf tube. The sample was chilled on ice until cool, 300 μL of chilled chloroform
and 200 μL of chilled methanol were added to the Eppendorf tube. The mixture was
vortexed for 15 seconds and then the solution was incubated over ice for 10 minutes. The
mixture was centrifuged at 15,000 x g at 4°C for 10 minutes. The mixture was poured
through a 0.2 μm nylon filter. The filter was pre-washed with 10 mM potassium
phosphate buffer. The filtrate had three layers, the upper aqueous phase, the pellet, and
the lower organic phase. The aqueous phase had a brownish tint after being filtered
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through the membrane. The organic layer was combined with the aqueous layer and put
into a speed vacuum concentrator to evaporate the liquid. The sample was removed from
the evaporator and diluted with 600 μL of 10 mM potassium phosphate butter. The
sample did not completely dissolve in solution. This solution along with 150 L of 5 mM
DSS with 0.1% (w/v) sodium azide in 100% D2O was added to an NMR tube and the
mixture was analyzed.

Figure 2.6.9.2. Sample 2 with 0.2 μm Syringe Filter
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2.6.10 Sample Preparation Modifications to Recover Metabolites from Aqueous and
Organic Phases using Filters with 10,000 Molecular Weight Cutoff
Sample 1
10,000 molecular weight cutoff micron ultracel YM-10 filters were pre washed
with 10 mM potassium phosphate buffer. The buffer was pipetted into an Eppendorf tube
that contained the filter and was centrifuged until the entire buffer filtered through the
membrane. This was done twice. 100 μL of 100 mM alanine, aspartic acid, glutamic
acid, and glucose were each pipetted into a 1.5 mL Eppendorf tube. 100 μL of 3 mM
BSA was also added to the Eppendorf tube. The sample solution was chilled over ice.
300 μL of chilled chloroform and 200 μL of chilled methanol were added to the
Eppendorf tube. The mixture was vortexed for 15 seconds and then incubated on ice for
10 minutes. The liquid portion of the mixture was transferred to eppendorf tubes
containing the pre washed filters. The liquid portion contained both the aqueous and
organic phases of the mixture. The liquid portion was centrifuged at 17,000 x g at 4°C
until all of the liquid filtered through leaving the BSA remaining on top of the filter. The
sample was put into a speed vacuum concentrator where it remained overnight until all of
the liquid evaporated leaving behind a residue. The sample was re-diluted with 600 μL
of 10 mM potassium phosphate buffer and 150 μL of 5 mM DSS with 0.1% sodium azide
in 100% D2O. This sample produced more metabolite recovery than sample 2. Since this
sample preparation produced the better recovery, it was repeated to establish
reproducibility and confirm initial results.
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Figure 2.6.10.1. Sample 1

Sample 2
10,000 molecular weight cutoff micron ultracel YM-10 filters were pre-washed
with 10 mM potassium phosphate buffer. The buffer was pipetted into an Eppendorf tube
that contained the filter and was centrifuged until the entire buffer filtered through the
membrane. This was done twice. 100 μL of 100 mM alanine, aspartic acid, glutamic
acid, and glucose were each pipetted into a 1.5 mL Eppendorf tube. 100 μL of 3 mM
BSA was also added to the eppendorf tube. The sample solution was chilled over ice.
300 μL of chilled chloroform and 200 μL of chilled methanol were added to the
Eppendorf tube. The mixture was vortexed for 15 seconds and then incubated on ice for
10 minutes. The entire mixture was centrifuged at 17,000 x g at 4°C for 10 minutes. The
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upper aqueous phase and lower organic phase were removed separately and transferred to
different eppendorf tubes that contained the pre-washed filters. Both phases were at
centrifuged at 17,000 x g at 4°C until all of the liquid filtered through leaving the BSA
remaining on top of the filter. The sample aliquots were combined into one Eppendorf
tube and put into a speed vacuum concentrator where it remained overnight until all of
the liquid evaporated leaving behind a residue. The sample was re-diluted with 600 μL
of 10 mM potassium phosphate buffer and 150 μL of 5 mM DSS with 0.1% sodium azide
in 100% D2O. The sample was analyzed on the NMR.

Figure 2.6.10.2. Sample 2
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2.6.11 Spiked Glutamic Acid in 100 mM Potassium Phosphate Buffer
Glutamic acid was not quantifiable in 3.6.10 sample 1 even though sample 1
produced the greatest amount of metabolite recovery in comparison to 2.6.10 sample 2.
As a result, a spiked glutamic acid sample was prepared using 100 mM potassium
phosphate buffer in order to determine if the10 mM buffer was properly buffering the
sample solution at a pH of 7.0. 75 μL of the 100 mM stock standards of alanine, aspartic
acid, and glucose were pipetted into a 5 mm NMR tube. 375 μL of 100 mM glutamic
acid stock standard solution and 150 μL of 5 mM DSS with 0.1% sodium azide in 100%
D2O were transferred to the same NMR tube and the solution was analyzed.

Figure 2.6.11.1. Spiked Glutamic Acid in 10 mM Potassium Phosphate Buffer
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Figure 2.6.11.2. Spiked Glutamic Acid in 100 mM Potassium Phosphate Buffer

2.7 Spectral Analysis and Processing
NMR analysis was carried out using the parameters listed in Table 2.2 and Figure
2.7. The free induction decay (FID) data, the observable signal produced by the NMR
was downloaded from the NMR onto a computer using FileZilla. The FID data was
retrieved from FileZilla and processed into spectral form using MestreNova. Once the
spectrum was opened, the reference option was selected from the analysis tab and the
DSS peak was assigned as the peak of reference for the spectrum. Next, ‘Manual
Correction’ was selected from the ‘Phase Correction’ scroll down menu. The pivot used
for phase adjustment was positioned to the right of the reference peak. Phase adjustment
took place by clicking the mouse button and moving the mouse up or down until peak
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phase correction was satisfactory. Manual baseline correction was selected under the
processing tab. Polynomial fit was chosen. Signal suppression for the water peak
occurred at 4.81 ppm. The processing template was saved for future use and to ensure
that all of the spectra were processed under the same conditions. Under the analysis tab,
manual peak picking, peak by peak, was selected and the peaks in the spectrum were
assigned chemical shift values. J-values were determined by selecting the manual peak
integration option and highlighting the peaks of interest. Spiking the standards and using
the Human Metabolome Database (HMDB) assisted in making peak assignments and
integrating. Right clicking on the J-value opened up the multiplet manager, which
allowed multiplet parameters to be set. These parameters included the peak name, the
number of hydrogens that it represented, and what type of splitting occurred. A function
within MestreNova was used to determine the concentrations of the standards in the
artificial fluid.. To do this, concentration was selected under the assignments tab. The
settings options arose on the screen. Under the calculations tab, internal reference was
selected. The range that the reference peak spanned on the spectrum was entered as well
as the reference standard concentration of 5 mM. The nuclides of reference were the nine
hydrogens that are part of the trimethylsilyl group on DSS which causes it to be highly
shielded and shifted furthest upfield in the spectrum. After the desired settings were
applied the settings window display was closed and calculate was selected. MestreNova
calculated the peak concentrations, which were presented in a results table.
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Table 2.2 NMR Analysis Conditions
NMR Protocol Parameters
Solvent
10% D2O
Temperature
25°C
Pulse Sequence
NOESY
Experiment
1D
Number of Scans
8.0000
Receiver Gain
20
Relaxation Delay
25.0000
Pulse Width
6.0000
Presaturation Frequency 4.64785
Acquisition Time
4.0000
Spectrometer Frequency 499.92
Spectral Width
7998.4
Lowest Frequency
-1675.7
Nucleus
1H
Acquired Size
31994
Spectral Size
65536
Digital Resolution
0.12

Figure 2.7. NOESY Pulse Sequence
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CHAPTER 3

GTT, ITT, terminal fasting blood glucose, hormone and cytokine/chemokine
multiplex array, pancreatic histological examination, and NMR metabolomics
method development performed to determine progress of insulin resistance in the
LEW.1WR1 rat model

3.1 Results
Body mass and food consumption for LEW.1WR1 (1WR1) and LEW/SsNHsd (SsNHsd)
rat groups were recorded over the 10 week study. The rats were 6-7 weeks old at the start
of the study. Body mass was used to observe diet specific side effects on the rat strains.
The rapid growth phase from 0 to roughly 20 days was undifferentiated among the rat
groups, after which changes in mass accumulation could be seen. In Figure 3.1A, the
1WR1 control rat group mirrored the SsNHsd high fat diet (HFD) rat group’s growth
curve. The SsNHsd control rat group gained the least amount of weight over the course
of the experiment. The SsNHsd HFD rat group, 1WR1 control rat group, and 1WR1
HFD rat group all deviated from the 1WR1 control rat group’s weight gain. Food
consumption in Figure 3.1B showed that the SsNHsd HFD rat group, 1WR1 control rat
group, 1WR1 HFD rat group varied from the SsNHsd control rat group.
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Figure 3.1. (A) Body Mass and (B) Food Consumption. Body Mass was measured
twice a week for 10 weeks. Food consumption was measured twice a week for 9.5
weeks. Error bars represent SD of n=7 rats per group.
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Figure 3.2. Pre-Diet (A) Glucose Tolerance Test and (B) Area under the Curve. Before
separating the animals into diet specific groups, the 1WR1 and SsNHsd rat groups were
subjected to a glucose tolerance test. The experiment was performed at a fasting state (4
hours). The curves showed no significant differences. The sum of the area under each
curve was graphed in arbitrary units. Error bars represent SD of n=14 per group.

Over the course of the baseline GTT, the curves in Figure 3.2A, showed that the
1WR1 rat group and the SsNHsd rat group had comparable blood glucose concentrations.
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Area under the curve (AUC) was computed for specific XY values between a defined
baseline and each curve, starting from the first X value in the data set and ending in the
largest X value. The area was ΔX*(Y1+Y2)/2. Statistical software used this formula
repeatedly for each adjacent pair of points defining the curve. AUC in pharmacokinetics
is a calculation of the concentration of a drug in the blood over time, which is expressed
as a measurement of exposure that alters the body’s physiology.1 AUC provides a
visually simplified way to compare graphical data by integrating curves.2 For instance,
two curves may look visually dissimilar; yet upon integration have indistinguishable
areas. In Figure 3.2B, the AUC measured the rat groups’ exposure to glucose. AUC is a
measurement of how much glucose is in the blood over a given amount of time. There
appeared to be no significant differences in the AUC for each rat model which means that
the rat groups’ exposure to glucose was similar.
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Figure 3.3. Insulin Tolerance Test (A) Four Weeks into Diet and (B) Area under the
Curve. The insulin tolerance test reflected blood glucose measurements after four weeks
on the diet. AUC reflected significant differences between the 1WR1 HFD rat group and
the SsNHsd control rat group. Reported Error represent SD of N=7 per group. Different
letters represent p<0.05 differences.

The insulin tolerance test (ITT) was used to measure the rat groups’
responsiveness to insulin. The ITT was performed after 4 weeks on the special diet. The
rats were 10-11 weeks old. Figure 3.3A showed that the 1WR1 HFD rat group
maintained higher blood glucose levels over the duration of the test. The SsNHsd HFD
rat group had the same initial baseline blood glucose levels as the 1WR1 HFD rat group,
but the SsNHsd HFD rat group’s blood glucose levels decreased in concentration as the
test progressed, reflecting similar blood glucose levels as the 1WR1 control rat group for
the 60 and 90 minute time points. The SsNHsd control rat group had the same initial
baseline blood glucose concentration as the 1WR1 control rat group; however, the
SsNHsd control rat group had persistently lower blood glucose levels than the rest of the
rat groups after the initial baseline glucose blood sugar reading. In Figure 3.3B, the AUC
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showed significant differences between the 1WR1 HFD rat group and the SsNHsd
control rat group.
A second GTT was carried out after eight weeks on the diet. The test was used to
measure any changes in glucose metabolism. The test allowed for any noticeable changes
in blood sugar concentration to be observed. The rats were 14-15 weeks old. In Figure
3.4A, the 1WR1 HFD rat group and the SsNHsd HFD rat group both had higher baseline
blood glucose concentrations than either control rat group.
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Figure 3.4. Eight Week (A) Glucose Tolerance Test and (B) Area under the Curve. A
glucose tolerance test was performed 8 weeks into the diet. The experiment was
conducted at fasting state (8 hours). The area under the curve shows significant
differences between the 1WR1 HFD rat group and the SsNHsd control rat group. Error
bars represent SD of n=7 rats. Different letters represent p<0.05 differences.

At the 30 minute time point, all of the other rat groups were significantly higher than the
SsNHsd control rat group. Additionally, the 1WR1 HFD rat group had the highest blood
glucose levels at both the 60 and 90 minute time points. The 1WR1 HFD rat group
consistently maintained higher blood glucose concentrations throughout the duration of
the study. Conversely, the SsNHsd control rat group retained the lowest blood glucose
levels over the course of this test. The overall area under the curve in Figure 3.4B
displays a significant difference between the integration of the curves in 3.4A for the
1WR1 HFD rat group and the SsNHsd control rat group.
In Table 3.1, there were no significant differences between values. However, the
1WR1 control rat group’s blood glucose increased as testing progressed. The 1WR1
HFD and SsNHsd HFD rat groups’ fasting blood glucose increased from the Pre-Diet
GTT to the ITT, peaked at the 8 week GTT, and then decreased when the terminal fasting
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blood glucose was taken. The terminal fasting blood glucose for the rat groups was taken
prior to sacrifice, while the animals were anesthetized. The 1WR1 control rat group had
a significantly higher blood glucose level than the 1WR1 HFD rat group. The SsNHsd
HFD rat group had an increased blood glucose level in comparison to the SsNHsd control
rat group; yet, there was no significant difference between these two groups. The
SsNHsd control rat group had the smallest amount of change in fasting blood glucose
values when compared to the other rat groups, because there was a difference of no more
than 8 mg/dL between this group’s smallest and largest values.

Table 3.1. Fasting Blood Glucose Levels across Tests. This table reports fasting blood
glucose levels for each glucose and insulin tolerance test and the final terminal fasting
blood glucose levels. The rats were anesthetized when the terminal fasting blood glucose
was collected. Different letters represent p<0.05 differences.

Rat Groups
1WR1 Control
1WR1 HFD
SsNHsd Control
SsNHsd HFD

Pre-Diet GTT
Fasting BG
(mg/dL)
108 +/- 20
115 +/- 10
116 +/- 13
122 +/- 19

ITT
Fasting BG
(mg/dL)
109 +/- 11
132 +/- 16
113 +/- 15
131 +/- 34

8 Week GTT
Fasting BG
(mg/dL)
119 +/- 27
150 +/- 26
116 +/- 15
158 +/- 61

Terminal
Fasting BG
(mg/dL)
150 +/- 31 a
109 +/- 24 b
121 +/- 22 a,b
134 +/- 27 a,b .

Figure 3.5. XS (A), S (B), M (C), and L (D) Islet Size Comparison. These islets
represent the size differentiation used to score the pancreas slides. Magnification was set
to 4x(500μm)
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Figure 3.6. Beta cell size scoring totals. XS (A), S (B), M (C), and L (D), and Total
Islets (E). This data represents the totals in size scoring of the islets. Different letters
represent p<0.05 differences. Error bars are SD of N=4,4,3,&4 samples with two sections
of pancreas analyzed for each rat, giving a sample size of n=2.

Islet size and number were assessed in the pancreata. The rats were 16-17 weeks
old at the time of harvest. Blinded scorers assessed the size and number of islets in two
sections of pancreas per rat. This data was compiled and analyzed for patterns relative to
rat strain and diet. There were more extra small islets for both control rat groups when
compared to their corresponding HFD rat groups. The 1WR1 rat groups did not differ
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significantly with regard to the number of small islets each rat group had. The SsNHsd
control rat group had more small islets than the SsNHsd HFD rat group. For medium
islets, each control rat group had more islets than their corresponding HFD rat group.
The SsNHsd control rat group had fewer large islets than the SsNHsd HFD rat group.
There was a significant difference between the 1WR1 control rat group and 1WR1 HFD
rat group, with the 1WR1 HFD rat group having a notably less amount of large islets
when compared to the 1WR1 control rat group. The SsNHsd HFD rat group had a
greater amount of large islets than the SsNHsd control rat group. For the total amount of
islets in the pancreatic cells, the control rat groups had more than the HFD rat groups.
The 1WR1 HFD rat group was significantly different than the SsNHsd control rat group.
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Figure 3.7. Terminal Multiplex Hormonal Array. This data represents the metabolic
hormonal array. Error bars are SD of n=7. Different letters represent p<0.05
differences.

Figure 3.8. Terminal Multiplex Hormonal and Cytokine/Chemokine Array. This data
represents the hormonal and cytokine/chemokine array. Error bars are SD of n=7.
Different letters represent p<0.05 differences.

Multiplex bead assays provide quantitative measurement for multiple analytes for
clinical and research purposes.3 This study used microbead-based suspension assays with
the BioPlex 200 platform carried out by Eve Technologies. In Figure 3.7, the insulin
concentration for the 1WR1 control rat group was significantly higher than the 1WR1
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HFD rat group. The 1WR1 control rat group had increased ghrelin, amylin, glucagon,
and GLP-1 when compared to the 1WR1 HFD rat group, but less peptide YY (PYY).
The SsNHsd control rat group had significantly less leptin than the SsNHsd HFD rat
group. The SsNHsd control rat group had less of every hormone than the SsNHsd HFD
rat group except for GLP-1. Both HFD rat groups had increased pancreatic polypeptide
(PP) in comparison to their corresponding control rat group.
In Figure 3.8, the 1WR1 control rat group had more MCP-1, C-peptide, IL-6, and
IL-12 over the 1WR1 HFD rat group. The 1WR1 HFD rat group had more LIX and
RANTES than the 1WR1 control rat group. The SsNHsd control rat group had increased
MCP-1, IL-6, IL-12, LIX, and RANTES in comparison to the SsNHsd HFD rat group.
The SsNHsd HFD rat group had more C-peptide than the SsNHsd control rat group.

Figure 3.9. Abdominal, Visceral, Epididymal, and Total Fat. The data represents
abdominal and visceral, epididymal, and total fat accumulated by the rat groups. Error
bars are SD of n=7. Different letters represent p<0.05 differences.
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The data in Figure 3.9 represented the visceral fat pads collected at harvest and
then measured. The abdominal and visceral fat was increased for the HFD rat groups
when compared to the control rat groups. Epididymal fat showed an increase for the
SsNHsd HFD rat group that was significantly different than the SsNHsd control rat
group. There was an accumulation of total fat for the HFD rat groups that was
significantly higher than the control rat groups.

Figure 3.10. 1.6 mM Artificial Fluid with BSA PRESEAT 1H NMR
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Figure 3.11. Sample Preparation Modifications to Recover Metabolites from
Extraction Protocol C
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Figure 3.12. Spiked Glutamic Acid in 10 mM Potassium Phosphate Buffer

Table 3.2. Concentrations of Standard Peaks. Concentration of standard peaks from
extraction protocol.
Standard
Alanine
Glutamic Acid
Aspartic Acid
Glucose at 4.64
Glucose at 5.22

Concentration (mM)
9.5556
11.6837
11.756
1.643
0.8177
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The metabolomics study will use serum collected at sacrifice. Prior to utilizing
the serum, an extraction protocol was developed using artificial fluid which allowed for
removal of the prominent blood carrier protein, serum albumin. Figure 3.10 was the
initial spectrum of the artificial fluid that included serum albumin before extraction.
Figure 3.11 represents the portion of the developmental process where protocol
utilization was successful at removing enough serum albumin to retain a flat baseline.
Figure 3.12 is a spectrum of the standards of interest. The positions of the standards in
the spectrum were determined by sample spiking and by using the Human Metabolome
Database as a reference. The initial concentrations of the standards before the adapted
extraction protocol were 13mM. Table 3.2 lists the final concentrations after the
extraction took place. Alanine had a recovery of about 74%. Glutamic Acid and
Aspartic Acid had a recovery of 85%. The glucose peaks represent the two anomers αand β-D-glucose, due to ring-chain tautomerism of the linear form of glucose. All of
these forms are present in solution with the alpha and beta anomers in a ratio of 36:64
and the linear form and furanose forms of glucose being less than 1 percent in solution.
In Table 3.2, the recovery of glucose is low and more protocol developments have to be
made in order to recover this standard in higher amounts.

Discussion
The mass accrual of the rats over the experimental period was an indicator of normal
growth and later possible obesity (Figure 3.1). Both HFD rat groups accumulated more
fat over the course of the study than the control rat groups. The SsNHsd HFD rat group
had an increased body fat percentage in comparison to the other rat groups while the
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1WR1 control rat group had the lesser amount. Sacrifices for both rat groups occurred
when the rats were about 16-17 weeks old. Rats are weaned at 3 weeks old and sexually
mature at 6 weeks.4 Transition to adulthood begins at 8 weeks and rats live for
approximately 3 years.4 According to Charles River, a well-known company that breeds
rat models for animal research, at 15 weeks old three male rat models were no more than
500g with the obese Zucker rat weighing in at about 650g.5–7 The Zucker rat is a
commonly used rat model for obesity studies because it has mutations in the leptin
hormone receptor.8 The reduced energy expenditure that these rats have along with
increased appetite due to the leptin receptor mutation leads to morbid obesity.8,9 None of
the rats exceeded a body mass of 500g. Yet, the SsNHsd control rat group weighed the
least in comparison to the other rat groups while the 1WR1 HFD rat group weighed the
most. Final weights for the rat groups were 381.03 +/- 0.30 g for the 1WR1 control rat
group, 424.56 +/- 0.02 g for the 1WR1 HFD rat group, 335.50 +/- 0.03 for the SsNHsd
control rat group, and 358.92 +/- 0.03 for the SsNHsd HFD rat group. The SsNHsd
control rat group weighed the least amount over the length of the study. Excess eating
has been associated with the limited use of glucose in metabolism.10 The 1WR1 control
rat group consistently consumed more food than the other rats, while the SsNHsd HFD
rat group consumed the least amount of food over the testing period. Also, insulin plays
a major role in increased adiposity leading to obesity.11 Adipose tissue is the primary
energy reservoir for the body and stores energy in the form triglycerides and releases
energy in the form of free fatty acids and glycerol.12 Adipose tissue secretes leptin and
adiponectin to control feeding behavior and also produces anti- and pro- inflammatory
adipokines to regulate inflammatory responses.13 Adipocytes, the most plentiful cells in
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adipose tissue, provide a reversible excess energy depot in adipose tissue.13 Excess
nutrition leads to hyperplasia and hypertrophy in the adipocytes which causes cellular
stress.13 Cellular stress initiates oxidative stress and inflammatory responses leading to
increased proinflammatory cytokines such as tumor necrosis factor (TNF-α), interleukin6 (IL-6), IL-1β, and CC-chemokine 2 (CCL2) which all contribute to insulin resistance.13
High levels of free fatty acids in blood plasma are associated with obesity.14,15 Not only
does obesity affect the production of free fatty acids but it also causes abnormal secretion
of adipokines from adipose tissues.16
The pre-diet GTT, in Figure 3.2, established a normalized baseline among the
1WR1 and SsNHsd rats before the experimental diet was changed. The fasting blood
glucose levels of all of the rats were in the pre-diabetic range for the initial blood glucose
measurement for the ITT at 4 weeks. Prediabetes is defined as blood glucose
concentrations higher than normal but below diabetic thresholds.17 The World Health
Organization (WHO) determines prediabetes as impaired fasting glucose (IFG) defined as
fasting plasma glucose (FPG) of 6.1-6.9 mmol/L (110 to 125 mg/dL) and impaired
glucose tolerance (IGT) defined as having a 2 hour plasma glucose of 7.8-11.0 mmol/L
(140-200 mg/dL) after ingestion of 75 g of an oral glucose load or a combination of the
two based on a 2 hour oral glucose tolerance test (OGTT).18,19 The American Diabetes
Association (ADA), on the other hand has the same cut-off value for IGT (140-200
mg/dL) but has a lower cut-off value for IFG (100-125 mg/dL) and has additional
hemoglobin A1c (HbA1c) based criteria of a level of 5.7% to 6.4% for the definition of
prediabetes.19,20
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Significant differences were observed at the 8 week glucose tolerance test after the
glucose load at the 30-minute time point, in Figure 3.4. At this time point, the other rat
groups deviated from the SsNHsd control rat group significantly; with the SsNHsd
control rat group had a lower amount of blood glucose. The 30 minute time point
showed how well the animals handle an influx of glucose, for instance, after a meal. This
could potentially mean that the other groups were not absorbing a glucose load as well as
the SsNHsd control rat group. The 1WR1 HFD rat group, 1WR1 control rat group, and
the SsNHsd HFD rat group had higher blood glucose concentrations at the 8 week 30minute time point than at the 30 minute time point occurring during the pre-diet GTT. It
seems that these rats were becoming more glucose intolerant because of their decreased
ability to absorb the glucose that they were given after fasting. The SsNHsd control rat
group was significantly different than the other three rats and had the lowest blood
glucose values over the length of the test. The glucose concentration for the SsNHsd
control rat was maintained under 200 mg/dL for the duration of testing for both GTT’s.
This means that there are potential metabolic disruptions that are occurring among the
other groups to inhibit optimal functioning. This susceptibility to disease due to
metabolic decline is also associated with aging and is another contributory factor leading
to increased morbidity.
Glucose tolerance tests were used to measure the amount of glucose in the rat
groups’ blood immediately after fasting and following a glucose load. Distinctive
features of the curves of the plotted data can help recognize differences in insulin
secretion and sensitivity.21,22 Simple biomarkers such as fasting blood glucose
concentrations can identify impaired beta cell function thus leading to type 2 diabetes.21–
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Monophasic insulin secretion transpires when glucose stimulates insulin secretion by

triggering and amplifying signals in beta cells.25,26 Biphasic insulin secretion happens
along both K+ dependent and K+ independent pathways.25,27 Based on examination of the
curves, biphasic or monophasic insulin secretion, in response to the glucose load, can be
concluded; with the monophasic group having lower hepatic and peripheral insulin
sensitivity and beta cell function.21,22 The 1WR1 HFD rat group maintained the highest
blood sugar levels, which means this rat group was not as sensitive to insulin as much as
the other rat groups were. The significant difference in the ITT area under the curve
between the 1WR1 HFD and the SsNHsd control rat groups may possibly represent two
opposite ends of the spectrum where the 1WR1 HFD rat group is becoming less sensitive
to insulin while the SsNHsd control rat group has the greater sensitivity among the all of
the groups. In Table 3.1, the fasting blood glucose levels increase across the tests for the
1WR1 HFD rat group, 1WR1 control rat group, and the SsNHsd HFD rat group. When
comparing the fasting blood glucose concentrations of the 1WR1 HFD rat group to the
1WR1 control rat group the differences between their increases across the tests was
greater for the 1WR1 HFD rat group. This means that the high fat diet exacerbated
glucose intolerance among the 1WR1 rat groups. The same observation applies to the
SsNHsd HFD and control rat groups. This supports the idea that a diet high in fat
promotes morbidity.
In Figure 3.6, the SsNHsd control rat group had more XS, S, M and total islets than
the SsNHsd HFD rat group. Based on the data, the SsNHsd HFD rat group had fewer
islets than the SsNHsd control rat group, higher terminal blood glucose levels, and higher
insulin levels. Apparently, there is an obvious signaling issue that may be causing the
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SsNHsd HFD rat group to develop insulin resistance. The 1WR1 control rat group had
more XS, M, L, and total islets than the 1WR1 HFD rat group. This means that the
1WR1 HFD rat group should have had more glucose at the terminal blood glucose
collection and less insulin than the 1WR1 control rat group if there was no signaling
impairment along the glucose pathway. According to the data, the 1WR1 HFD rat group
had less terminal blood glucose, less insulin and fewer islets than the 1WR1 control rat
group. This insinuates that there was a signally issue which means that the IWR1 HFD
rat group was experiencing beta cell death and dumping insulin. The 1WR1 control rat
group had elevated insulin and blood glucose concentrations when compared to the
SsNHsd control rat group. In addition, the 1WR1 control rat group had fewer XS, S, M,
and total islets than the SsNHsd control rat group which means that this rat group could
be developing insulin resistance.
Hormones and cytokines are involved in metabolism regulation and response. They
participate in many biological functions and can provide clues as to what is occurring
metabolically. Insulin stimulates the uptake of glucose in adipocytes and therefore
induces the expression and secretion of MCP-1 or CCL2 in these fat cells.28 This means
that in individuals with normal glucose metabolic activity and sensitivity to insulin there
is a higher concentration of MCP-1 in the blood than those with decreasing insulin
sensitivity. Amylin is hormone found in the pancreatic beta cell and is cosecreted with
insulin at about 15:1.29–31 C-peptide is part of proinsulin and is cleaved upon cosecretion
with insulin.32 As insulin resistance develops for these rat groups they should have
increased amounts of c-peptide, amylin and glucose in their blood serum. This is
reflected in Figure 3.7 and Figure 3.8 with the HFD rat groups being more concentrated
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then the control rat groups. Glucagon is a hormone that is secreted by pancreatic alpha
cells in response to low blood glucose levels in the body.33 If the body is developing
insulin resistance than there are high concentrations of insulin in the blood that the body
is not responding to. In other words, since glucagon is a counter-regulatory hormone of
insulin, the concentrations of glucagon in relation to insulin should be opposite of
insulin.33 However, in Figure 3.7, the concentrations of insulin and glucagon are not
opposite of one another. Inflammatory responses induced by obesity impair insulin
signaling in insulin responsive organs which leads to insulin resistance prior to the
development of type 2 diabetes.11,34 RANTES or CCL5 is a proinflammatory mediator
that participates in immune response by supporting the survival of immune inflammatory
cells responding to injury or infection.35–37 Plainly, the presence of RANTES limits the
ability of insulin signaling to insulin responsive organs in order to secrete insulin and
regulate glucose metabolic activity. In Figure 3.8, this means that for the rat groups that
have higher concentrations of insulin there should be lower concentrations of RANTES.
This is true when comparing the concentrations of RANTES and insulin for the rat
groups. SsNHsd control rat group has a higher concentration of MCP-1 in its blood
serum than the SsNHsd HFD rat group. In addition, the 1WR1 control rat group has
more MCP-1 than the 1WR1 HFD rat group. LIX (CXCL5 or ENA-78) is a chemokine
that is also secreted by adipose tissue and increased during obesity and excess circulating
LIX inhibits insulin action in muscle by activating the JAK/STAT signaling pathway;
thus, inducing insulin resistance.38 The JAK/STAT signaling pathway is cascade of
signal transductions involved in development and homeostasis in mammals.39,40 The
1WR1 HFD rat group has a higher concentration of LIX than the 1WR1 control rat
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group. However, the SsNHsd HFD rat group has less LIX than the SsNHsd control rat
group.
The fat measurements in Figure 3.9 are abdominal and visceral, epididymal, and
total fat. Visceral fat is found in the abdominal cavity and around organs.41 Visceral and
abdominal fat are associated with excess accumulation of free fatty acids and obesity.42
Even in non-obese subjects, increased visceral fat has been correlated to individuals
suffering from coronary artery disease.42 In addition, the removal of visceral fat in
diabetic aging rats has been shown to increase plasma insulin levels; thereby improving
insulin action.43 In Figure 3.9, both HFD rat groups have increased visceral and
abdominal fat over the control rat groups. Also, these differences were significant. In
addition, both HFD rat groups have significantly more total fat than the control rat
groups. Epididymal fat is visceral fat found in the perigonadal region known as
epididymal in male rats.41 The SsNHsd HFD rat group had significantly more
epididymal fat than the SsNHsd rat control group.
The initial NMR spectrum in Figure 3.10 represents the artificial fluid including the
serum albumin prior to performing the extraction protocol recorded in the paper written
by John Sheedy.44 This was a one-dimensional presaturation spectrum (PRESAT) used
to suppress the water peak at 4.75 ppm. In order to develop the protocol, an initial
spectrum had to be taken to determine a starting point for analysis. Simply put, it was
necessary to see how the spectrum looked before sample manipulation. This spectrum
did not have a flat baseline and there appeared to be peak overlaps and distortions. This
occurred because serum albumin binds different classes of ligands at different sites on the
protein in order to transport these ligands in the blood. Thus, it was necessary to remove
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it from solution so that peak assignments could be made and high recovery yields could
be obtained. Unfortunately, several attempts to duplicate extraction protocol c from the
paper written by John Sheedy did not produce a flat baseline or similar yields. Upon
manipulation of this extraction protocol, it was discovered that the metabolites of interest
were in both the aqueous and organic phases of the mixture. As a result the protocol was
modified from extraction protocol C, Figure 3.11 shows a pivotal point in analysis where
the serum albumin appeared to be removed from solution upon observation of a flat
baseline. At this stage, further development was needed to acquire recovery yields and
establish reproducibility. Figure 3.12 is the spectrum and recovery after several trials
using the modified protocol. Higher metabolite recovery is still needed before the serum
samples can be analyzed.

Conclusion
Type 2 diabetes is a disease that is affecting a large portion of the world
population. The occurrence of this disease increases in individuals as they age. Lifestyle
habits and factors impeding good health, such as obesity, have also contributed to its
progression over time. Learning more about type 2 diabetes by studying how it develops
and the circumstances that increase its prevalence in aging individuals will help scientists
and medical professionals provide better treatment options and improve the quality of life
for people who have this disease and for those who are predisposed to getting it. Animal
models, like the 1WR1 rat model, provide researchers with a reasonable way to examine
the effects of factors like aging and obesity on type 2 diabetes, in living beings. The
1WR1 control rat group was representative of this.
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Aging leads to metabolic decline overtime because the body is not working as
well as it use to; thus, making it more susceptible to poor health conditions, such as
weight gain. This was visible with the 1WR1 control rat group as the rat group’s final
weight of 381.03 +/- 0.30 g was greater than the SsNHsd control rat group’s final weight
of 335.50 +/- 0.03 g. Also, the 1WR1 control rat group had more visceral and abdominal,
epididymal, and total fat than the SsNHsd control rat group.
Glucose intolerance is a prediabetic state where fasting blood glucose levels
surpass the normal range while staying below the diabetic range. This range exceeds the
normal fasting blood glucose levels for mice from 50-100 mg/dL but is less than the
diabetic fasting blood glucose range of 150-300 mg/dL.45 The terminal fasting blood
glucose concentration for the 1WR1 control rat group was 150 mg/dL while the SsNHsd
control rat group’s terminal fasting blood glucose was 121 mg/dL. In other words, the
terminal fasting blood glucose value for the 1WR1 control rat group was at the lowest
end of the diabetic fasting blood glucose range. The 1WR1 control rat group had fewer
islets than the SsNHsd control rat group, which means that the 1WR1 control rat group
was secreted less insulin.
Disruptions in normal hormonal signaling arise when the body is in an unhealthy
state. This occurred in the 1WR1 control rat group. This rat group had higher levels of
C-peptide than the SsNHsd control rat group yet lower levels of insulin. C-peptide is a
part of proinsulin and is cleaved from insulin prior to it being packaged into secretory
vesicles for secretion. It is used as a marker of insulin secretion because equimolar
amounts are stored in secretory granules in pancreatic beta cells. The 1WR1control rat
group also had higher levels of leptin and PYY than the SsNHsd control rat group lower
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levels of the ghrelin and proinflammatory chemokines, IL-6 and IL-12. This means that
the 1WR1 control group was receiving hormonal signals to stop eating and storing fat yet
continued eating which is evident because they weighed more than the SsNHsd control
rat group. Also, since inflammation is associated with weight gain and obesity the 1WR1
control rat group should have higher levels of IL-6 and IL-12 than the SsNHsd control rat
group.
The 1WR1 control rat group had increased weight gain and disruptions in normal
metabolic functioning in comparison to the SsNHsd control rat group. The 1WR1 control
rat group also had fasting blood glucose concentrations that were closer to the diabetic
range than the SsNHsd control rat group. This evidence suggests that this rat group is
glucose intolerant.
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